Study of Interleukin 2 with and without Levamisole in Cancer Patients
Author Information
Author(s): FY Ahmed, GA Leonard, R A'Hern, AE Taylor, A Lorentzos, H Atkinson, J Moore, MC Nicolson, PG Riches, ME Gore
Primary Institution: Royal Marsden Hospital
Hypothesis
Does the addition of levamisole to subcutaneous interleukin-2 improve its efficacy in patients with metastatic renal cell carcinoma or malignant melanoma?
Conclusion
Subcutaneous interleukin-2 can be safely administered in an outpatient setting, but levamisole did not enhance its immunological effects.
Supporting Evidence
- Two patients with metastatic melanoma responded to treatment, both receiving IL-2 alone.
- Significant increases in immune markers were observed after treatment with IL-2.
- Levamisole did not significantly change any immunological parameters.
Takeaway
Doctors tested a treatment using a medicine called interleukin-2 to help cancer patients, but adding another medicine, levamisole, didn't make it work better.
Methodology
Patients were randomized to receive two different doses of interleukin-2 with or without levamisole for three months, and their immune responses were monitored.
Potential Biases
Potential biases in patient selection and treatment allocation.
Limitations
The study had a small sample size and lacked a control group for comparison.
Participant Demographics
Patients with metastatic renal cell carcinoma or malignant melanoma, aged 18 and over.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website